Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With KRAS/NRAS/BRAF Wild-Type Microsatellite Stable Metastatic Colorectal Cancer Impaired homologous recombination–mediated DNA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback